Kaken Pharmaceutical (4521) R&D Day 2025 summary

Pipeline overview and program updates

• Pipeline spans rare disease, immunology, dermatology, pain, oncology and regenerative medicine; late-stage assets include KAR, KP-001, KC-8025, ESK-001 and navenibart.

• KP-723, a low-molecular-weight oral STAT6 inhibitor for type 2 inflammation, was preclinical; development was planned through completion of Phase I before transfer to Johnson & Johnson.

• NM26, a bispecific antibody targeting IL-4Rα and IL-31, was in Phase II; KP-910 and KP-483 were in Phase I, and gMSC1 was being prepared for Phase III in knee osteoarthritis.

• Other programs included Phase III-preparation work for KP-001 in the US, Phase II ESK-001 psoriasis development, and imported navenibart for hereditary angioedema prevention.

Clinical trial data and development milestones

• KAR Phase III treatment success at 3 weeks was 85.2% with ivermectin 0.5% versus 7.4% with placebo; no serious adverse events occurred, and adverse events were mostly mild.

• KP-001's domestic Phase III study in 32 patients met its MRI-based primary endpoint: lesion volume reduction of at least 20% statistically exceeded the prespecified threshold; a long-term study was ongoing.

• KC-8025 global Phase III data showed ALP normalization at 12 months in 61.7% versus 20.0% on placebo; domestic Phase III enrollment was completed in October 2025.

• Sebetralstat relieved HAE symptoms in median 1.61 hours at 300 mg and 1.79 hours at 600 mg, versus 6.72 hours with placebo; no serious treatment-related adverse events were reported.

• Navenibart Phase I/II cohorts showed 91%–95% reductions in monthly attack frequency over 6 months; cohort sizes were 4–6, with no serious treatment-related adverse events.

R&D strategy and innovation priorities

• Priorities center on immunology, neurology and infectious disease, while expanding into unmet-need and rare-disease areas and pursuing new modalities beyond small molecules.

• Targets include faster development, higher probability of success, pipeline expansion through licensing and repositioning, global development, and digital applications in dermatology and orthopedics.

• AI drug discovery uses generated structures and prediction models; de novo screening achieved a 57% hit rate versus 9.6% for the compound library in the cited example.

• Data-driven discovery plans include building data infrastructure in FY2025, updating the discovery system in FY2026 and increasing active discovery projects toward FY2031.